About BIOMAP
Towards Personalised Medicine for Inflammatory Skin Diseases
BIOMAP will examine the causes and mechanisms of Atopic Dermatitis and Psoriasis to enable optimal treatments and an individualised therapy scheme for each patient.
Atopic Dermatitis and Psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment.
Duration
60 months
32 Partners
12 countries
Budget
21.2 Mio €
Introduction to BIOMAP
Videos
Disease Scope
Atopic Dermatitis
3.5%
global annual prevalence
atopic diseases, infections, psychiatric disorders, cardiovascular disease
common comorbidities
80%
heritability
Psoriasis
1.5%
global annual prevalence
arthritis, metabolic syndrome, psychiatric disorders, cardiovascular disease
common comorbidities
70%
heritability
Key Problems
High disease heterogeneity
Outdated disease classification
Limited understanding of underlying mechanisms
Lack of biomarkers for disease and therapy prediction
Insufficient infrastructure for global access to samples and data
BIOMAP Vision
To better define the heterogeneity and homogeneous aspects of atopic dermatitis and psoriasis and to develop new concepts for taxonomy and patient stratification
Approach
Network
To form a collaborative network of clinicians, researchers, patient organisations and industry partners
Biosamples
To establish a pan-European BioResource of samples aligned to high quality clinical data
Data Warehouse
To build a Data Warehouse with clinical, experimental and multi-omics data from large high-quality cohorts and industry trials
Data Modelling
To use cutting-edge integrative data modelling approaches